Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy (ERAMIP)

University Hospital, Gasthuisberg

Status: Completed

Conditions: Pancreatic Neoplasms; Periampullary Neoplasms

Treatments: Procedure: ERAMIP

Study type: Observational

Funder types: Other

Identifiers

NCT02671357

ERAMIP

Details and patient eligibility

About

This prospective observational cohort study aims to improve the postoperative course after minimally invasive pancreaticoduodenectomy (MIP) with stented pancreaticogastrostomy (sPG) for pancreatic head or peri-ampullary neoplasms. Patients are submitted to an enhanced recovery after surgery (ERAS) program with early enteral nutrition (EEN).

Full description

Pancreaticoduodenectomy (PD) is the standard of care for patients with malignant or benign disease of the pancreatic head or peri-ampullary region. The postoperative course after PD is strongly dependent of the occurrence of pancreatic fistula (POPF) and/or delayed gastric emptying (DGE). In a recent multicentre randomized controlled trial, the investigators have shown pancreaticogastrostomy (PG; without a stent in the pancreatic duct) to be associated with 8% POPF rate, significantly lower than pancreaticojejunostomy (20%) (1). Since then, PG reconstruction is considered the standard of care in PD, which is also underlined in more recent systematic reviews.

In patients without POPF after PD, the length of hospital stay is determined by the occurrence of DGE, which is poorly understood and currently lacks any effective treatment. Patients who developed DGE after PD with PG anastomosis (n=18; 20%) had a significantly (p=0.014) longer (mean + sem) length of hospital stay (LOS) of 26.3 + 1.58 days, as compared to 22.4 + 1.27 days for patients without DGE (n=69). These figures are observed in the investigators' center as part of the multicentre RCT.

Enhanced recovery after surgery (ERAS) or fast-track (FT) programs are able to reduce postoperative length of hospital stay (LOS). Indeed recently, ERAS or FT programs have been implemented successfully in PD (2). Patients were discharged 4 days earlier in the ERAS group, without a negative effect on the clinical outcome. Still, many surgeons are reluctant to implement ERAS programs because they fear compromising patient safety.

In efforts to improve the outcomes of PD, many surgical techniques have been evaluated to restore the pancreatic digestive continuity after PD. However, the best way to ensure this and whether or not to perform the procedure via standard open or minimally invasive, i.e. 2- or 3-dimensional laparoscopic (3D-LPD) or 3-dimensional robotic surgery (RPD), is still under debate. The investigators have passed the learning curve of 50 3D-LPD and hypothesize the implementation of ERAS and EEN in 3D-LPD can improve short-term outcomes.

Enrollment: 210 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients, male or female, who undergo MIP + sPG for a pancreatic or peri-ampullary tumor
• Patients with and without pre-operative biliary drainage (for obstructive jaundice)
• Patients fit for minimally invasive pancreaticoduodenectomy (MIP)
• Informed consent signed

Exclusion criteria

• Pregnancy
• MIP for pancreatic trauma
• MIP for complications of endoscopic retrograde cholangio-pancreaticography (ERCP)
• Reconstruction of the portal vein or superior mesenteric vein
• Any arterial reconstruction at the time of surgery

Trial design

210 participants in 1 patient group

ERAMIP with EEN

Description:

Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN

Treatment:

Procedure: ERAMIP